Pamela Price, NP
Family · Roanoke, VANPI 1346226636
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Pfizer at 42.3% of the total. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $52.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Genentech, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$973
- Sanofi$917
- GSK$265
- plus $1K from 18 others
Across 4 payments — averaging $1466.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$4K
- Astellas Pharma Global Development$2K
What the payments were for
- Consulting fees$3,89531%
- Speaking & faculty fees$4,05832%
- Food & beverage$4,49935%
- Education$2582%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $5,372 |
| Genentech, Inc. | 1 | $2,845 |
| Regeneron Healthcare Solutions, Inc. | 60 | $1,070 |
| AstraZeneca(2 entities) | 49 | $973 |
| Sanofi | 46 | $917 |
| GSK | 13 | $265 |
| Genentech USA, Inc. | 7 | $179 |
| Astellas Pharma US Inc | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $121 |
| Teva Pharmaceuticals USA, Inc. | 7 | $115 |
| CSL Behring | 5 | $113 |
| Biocryst US Sales Co., LLC | 3 | $98 |
| Novartis | 5 | $88 |
| Blueprint Medicines Corporation | 4 | $87 |
| Kaleo, Inc. | 5 | $84 |
| Optinose US, Inc. | 3 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Grifols USA, LLC | 1 | $28 |
| Incyte Corporation | 1 | $24 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $16 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Hospira, Inc. | 1 | $13 |
| Covis Pharma GmbH | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$125
How this compares
$12,709 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Arnuity ElliptaFluticasone Furoate | 117 | $37,256 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $36,424 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $22,257 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $17,831 |
| Qvar RedihalerBeclomethasone Dipropionate | 32 | $15,389 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $12,906 |
| Azelastine Hcl | 231 | $8,050 |
| Ipratropium Bromide | 216 | $6,635 |
| Epinephrine | 38 | $5,913 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $5,068 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,705 |
| Fluticasone Propionate | 161 | $2,657 |
| Montelukast Sodium | 241 | $1,763 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,203 |
| Mometasone Furoate | 11 | $1,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArnuity Ellipta, Breo Ellipta, Trelegy Ellipta | $265 | $95,938200 claims |
| AstraZenecaSymbicort | $973 | $17,83151 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $115 | $15,38932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Roanoke
- Jamie BrackenrichRoanoke$40K
- Jessica SaundersRoanoke$12K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.